Changes in somatic disease incidents during opioid maintenance treatment: results from a Norwegian cohort study

Ivar Skeie, Mette Brekke, Michael Gossop, Morten Lindbaek, Even Reinertsen, Magne Thoresen, Helge Waal, Ivar Skeie, Mette Brekke, Michael Gossop, Morten Lindbaek, Even Reinertsen, Magne Thoresen, Helge Waal

Abstract

Objectives To examine the effect of opioid maintenance treatment (OMT) on somatic morbidity in a cohort of OMT patients. Design Retrospective cohort study. Setting OMT programme in two Norwegian counties. Participants 200 OMT patients, participation rate 71.2%. Main outcome measures Incidence rates (IR) before, during and after OMT for acute/subacute hospital-treated somatic disease incidents (drug-related, non-drug-related, injuries) and rates for inpatient days and outpatient treatment contacts. Results IR for drug-related hospital treatment episodes were 76% lower during compared to before OMT (before versus during incidence rate ratio (IRR) 4.2 (95% CI 2.9 to 6.2), p<0.001) and 11 times higher after compared to during OMT (after versus during IRR 11.1 (6.6 to 18.5), p<0.001). For non-drug-related treatment episodes, IR were 35% higher during than before OMT (before versus during IRR 0.7 (0.6 to 1.0), p=0.02) and 32% higher after compared to during OMT (IRR 1.4 (0.9 to 2.2), p=0.15), while injuries showed little change according to OMT status. Although patients with on-going drug-taking during OMT showed less reduction in drug-related hospital-treated incidents during treatment than patients not using illicit drugs, the quartile with most drug-taking showed a significant reduction (before versus during IRR 3.6 (2.4 to 5.3)). Patients who had experienced cessation of OMT showed a significant reduction in drug-related treatment episodes during OMT (before versus during IRR 1.7 (1.0 to 2.9)), although less than patients without OMT interruptions (before versus during IRR 6.1 (3.6 to 10.6)), and a significant increase after OMT cessation compared with during OMT (IRR 5.4 (3.0 to 9.7)). Conclusion Acute/subacute drug-related somatic morbidity is reduced during compared to before OMT. This was also found for patients with on-going drug-taking during OMT. However, acute drug-related health problems show an increase after OMT cessation, and this is a matter of concern. Further studies on somatic morbidity after OMT cessation should be carried out.

Conflict of interest statement

Competing interests: <?release-delay 0|0 >None.

Figures

Figure 1
Figure 1
Participants: patients starting opioid maintenance treatment between 1998 and June 2007. The studied cohort consists of the 200 included patients.

References

    1. Fischer B, Rehm J, Brissette S, et al. Illicit opioid use in Canada: comparing social, health, and drug use characteristics of untreated users in five cities (OPICAN study). J Urban Health 2005;82:250–66
    1. Ross J, Teesson M, Darke S, et al. The characteristics of heroin users entering treatment: findings from the Australian treatment outcome study (ATOS). Drug Alcohol Rev 2005;24:411–18
    1. Popova S, Rehm J, Patra J, et al. Illegal drug-attributable morbidity in Canada 2002. Drug Alcohol Rev 2007;26:251–63
    1. Bijl RV, Ravelli A, van Zessen G. Prevalence of psychiatric disorder in the general population: results of The Netherlands Mental Health Survey and Incidence Study (NEMESIS). Soc Psychiatry Psychiatr Epidemiol 1998;33:587–95
    1. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arc Gen Psychiatry 1994;51:8–19
    1. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990;264:2511–18
    1. Millson PE, Challacombe L, Villeneuve PJ, et al. Self-perceived health among Canadian opiate users: a comparison to the general population and to other chronic disease populations. Can J Public Health 2004;95:99–103
    1. Puigdollers E, Domingo-Salvany A, Brugal MT, et al. Characteristics of heroin addicts entering methadone maintenance treatment: quality of life and gender. Subst Use Misuse 2004;39:1353–68
    1. Brugal MT, Domingo-Salvany A, Puig R, et al. Evaluating the impact of methadone maintenance programmes on mortality due to overdose and aids in a cohort of heroin users in Spain. Addiction 2005;100:981–9
    1. Darke S, Degenhardt L, Mattick R. Mortality Amongst Illicit Drug Users: Epidemiology, Causes and Intervention. Cambridge: Cambridge University Press, 2007
    1. Reimer J, Lorenzen J, Baetz B, et al. Multiple viral hepatitis in injection drug users and associated risk factors. J Gastroenterol Hepatol 2007;22:80–5
    1. Taylor A, Goldberg D, Hutchinson S, et al. Prevalence of hepatitis C virus infection among injecting drug users in Glasgow 1990-1996: are current harm reduction strategies working? J Infect 2000;40:176–83
    1. Hope V, Kimber J, Vickerman P, et al. Frequency, factors and costs associated with injection site infections: findings from a national multi-site survey of injecting drug users in England. BMC Infect Dis 2008;8:120.
    1. Bargagli AM, Hickman M, Davoli M, et al. Drug-related mortality and its impact on adult mortality in eight European countries. Eur J Public Health 2006;16:198–202
    1. WHO Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence. Geneva: World Health Organization, 2009
    1. Fischer B, Rehm J, Kim G, et al. Eyes wide shut?–A conceptual and empirical critique of methadone maintenance treatment. Eur Addict Res 2005;11:1–9; discussion 10–14.
    1. Darke S, Ross J, Teesson M. The Australian Treatment Outcome Study (ATOS): what have we learnt about treatment for heroin dependence? Drug Alcohol Rev 2007;26:49–54
    1. Gowing L, Farrell M, Bornemann R, et al. Substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev 2008;(2):CD004145.
    1. Dole VP, Nyswander ME, Kreek MJ. Narcotic blockade–a medical technique for stopping heroin use by addicts. Trans Assoc Am Physicians 1966;79:122–36
    1. Kreek MJ. Tolerance and dependence: implications for the pharmacological treatment of addiction. In: Harris LS, ed. NIDA Research Monograph 76-Problems of Drug Dependence 1986: Proceeding of the 48th Annual Scientific Meeting The Committee On Problems of Drug Dedpendence. Rockville: US Department of Health and Human Services, 1987:53–62
    1. Wittchen HU, Apelt SM, Soyka M, et al. Feasibility and outcome of substitution treatment of heroin-dependent patients in specialized substitution centers and primary care facilities in Germany: a naturalistic study in 2694 patients. Drug Alcohol Depend 2008;95:245–57
    1. Stenbacka M, Leifman A, Romelsjo A. The impact of methadone on consumption of inpatient care and mortality, with special reference to HIV status. Subst Use Misuse 1998;33:2819–34
    1. Romelsjo A, Engdahl B, Stenbacka M, et al. Were the changes to Sweden's maintenance treatment policy 2000-06 related to changes in opiate-related mortality and morbidity? Addiction 2010;105:1625–32
    1. Skeie I, Brekke M, Lindbaek M, et al. Somatic health among heroin addicts before and during opioid maintenance treatment: a retrospective cohort study. BMC public health 2008;8:43.
    1. Waal H, Clausen T, Håseth A, et al. Seraf Rapport 1/2010 (revidert utgave) Siste år med gamle retningslinjer Statusrapport 2009. Oslo: Norwegian Centre for Addiction Research, 2010
    1. Clausen T, Anchersen K, Waal H. Mortality prior to, during and after opioid maintenance treatment (OMT): a national prospective cross-registry study. Drug Alcohol Depend 2008;94:151–7
    1. Fugelstad A, Stenbacka M, Leifman A, et al. Methadone maintenance treatment: the balance between life-saving treatment and fatal poisonings. Addiction 2007;102:406–12
    1. Kimber J, Copeland L, Hickman M, et al. Survival and cessation in injecting drug users: prospective observational study of outcomes and effect of opiate substitution treatment. BMJ 2010;341:c3172.
    1. Caplehorn JR, Dalton MS, Haldar F, et al. Methadone maintenance and addicts' risk of fatal heroin overdose. Subst Use Misuse 1996;31:177–96
    1. Dolan KA, Shearer J, White B, et al. Four-year follow-up of imprisoned male heroin users and methadone treatment: mortality, re-incarceration and hepatitis C infection. Addiction 2005;100:820–8
    1. Gronbladh L, Ohlund LS, Gunne LM. Mortality in heroin addiction: impact of methadone treatment. Acta Psychiatr Scand 1990;82:223–7
    1. Zanis DA, Woody GE. One-year mortality rates following methadone treatment discharge. Drug Alcohol Depend 1998;52:257–60
    1. Cornish R, Macleod J, Strang J, et al. Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database. BMJ 2010;341:c5475.
    1. Davoli M, Bargagli AM, Perucci CA, et al. Risk of fatal overdose during and after specialist drug treatment: the VEdeTTE study, a national multi-site prospective cohort study. Addiction 2007;102:1954–9
    1. Degenhardt L, Randall D, Hall W, et al. Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved. Drug Alcohol Depend 2009;105:9–15
    1. Spijkerman IJ, van Ameijden EJ, Mientjes GH, et al. Human immunodeficiency virus infection and other risk factors for skin abscesses and endocarditis among injection drug users. J Clin Epidemiol 1996;49:1149–54
    1. Hope VD, Marongiu A, Parry JV, et al. The extent of injection site infection in injecting drug users: findings from a national surveillance study. Epidemiol Infect 2010;138:1510–18
    1. Godfrey C, Stewart D, Gossop M. Economic analysis of costs and consequences of the treatment of drug misuse: 2-year outcome data from the National Treatment Outcome Research Study (NTORS). Addiction 2004;99:697–707
    1. Millson P, Challacombe L, Villeneuve PJ, et al. Determinants of health-related quality of life of opiate users at entry to low-threshold methadone programs. Euro Addict Res 2006;12:74–82
    1. Cullen W, O'Brien S, O'Carroll A, et al. Chronic illness and multimorbidity among problem drug users: a comparative cross sectional pilot study in primary care. BMC Fam Pract 2009;10:25.
    1. Williamson A, Darke S, Ross J, et al. Changes and predictors of change in the physical health status of heroin users over 24 months. Addiction 2009;104:465–70
    1. Waal H. Merits and problems in high-threshold methadone maintenance treatment. Evaluation of medication-assisted rehabilitation in Norway 1998-2004. Euro Addict Res 2007;13:66–73

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit